secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001104659-24-130855
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec announces NICE recommends PEDMARQSI for cisplatin-induced hearing loss in children in England and Wales
--------------------------------------------------------------------------------

- NICE issued positive final draft guidance recommending PEDMARQSI for prevention of cisplatin-induced hearing loss in patients aged 1 month-17 years with localized solid tumors.
- First and only approved therapy in EU/U.K. for cisplatin-induced ototoxicity prevention; Phase 3 trials showed ~50% reduction in hearing loss.
- Fennec's partner Norgine will commercialize in Europe; Fennec received ~$43M upfront and is eligible for up to ~$230M milestones plus double-digit tiered royalties.
- Until now, no preventative pharmacological intervention was available despite significant lifelong impact of hearing loss on pediatric cancer patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924130855/0001104659-24-130855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924130855/tm2431725d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-130855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer